
In Extended Anticoagulant Treatment With a Reduced Versus Full Dose Apixaban in Patients With Cancer-Associated Venous Thromboembolism, get a deep dive into the API-CAT late-breaking clinical trial presented at ACC.25! It's just one of more than a thousand presentations from the conference, including inspiring keynotes, cutting-edge late-breaking clinical trials, thought-provoking panels and more. ACC.25 attendees with full three-day conference professional registration receive a FREE one-year subscription to ACC Anywhere – login to activate your account. Didn't attend ACC.25? Enjoy a free preview and subscribe to watch the full video, plus thousands more from ACC's top meetings!